Frontiers | Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders | Pharmacology
Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
Theravance Biopharma :: SEC Filing
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - The Lancet Gastroenterology & Hepatology
VELUSETRAG
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Current developments in pharmacological therapeutics for chronic constipation - ScienceDirect
Prokinetics in Phase II and III stages of development | Download Table
VELUSETRAG
Full article: Velusetrag for the treatment of chronic constipation
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis | Clinical Research Trial Listing ( Gastroparesis ) ( NCT01718938 )
Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. - Abstract - Europe PMC
Theravance Biopharma :: SEC Filing
Velusetrag - Wikiwand
Buy Velusetrag (bt-285965)| THE BioTek
Receptor binding profile of 5-HT 4 agonists for GI disorders, at... | Download Table
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Summary of Clinical Trials for Chronic Constipation | Download Table
Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Tryptophan Metabolism as a Pharmacological Target: Trends in Pharmacological Sciences
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5‐HT4 agonist with high intrinsic activity, in chronic idiopathic constipation – a 4‐week, randomized, double‐blind, placebo‐controlled, dose–response study - Goldberg - 2010 -
Is Alfasigma late reporting EU clinical trials?
Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial - ScienceDirect
PDF) Velusetrag for the treatment of chronic constipation
Theravance Biopharma :: SEC Filing
